Here, we provide, to the best of our knowledge, the first evidence of SIK2 downregulation, its contribution to breast cancer patient survival, and its potential tumor suppressor role in breast cancer cells, which can potentially be mediated by simultaneous blockage of Ras/ERK and PI3K/Akt pathways. This evidence concerns the gene SIK2 and neoplasm.